Bronchoscopic Lung Volume Reduction for Emphysema

Surya kant1* and Jyoti Bajpai

Department of Respiratory Medicine, University of Lucknow, India

Submission: March 10, 2017; Published: May 02, 2017

*Corresponding author: Surya kant, Department of Respiratory Medicine, University of Lucknow, India Tel: 9415016858, Email: skantpulmed@gmail.com

Background

Emphysema is pathologically defined as an abnormal permanent enlargement of air spaces distal to the terminal bronchioles, accompanied by the destruction of alveolar walls and without obvious fibrosis [1]. It is an irreversible disease and although patients derive significant benefit from inhaled therapies and pulmonary rehabilitation but many remain significantly disabled [2]. Lung volume reduction surgery (LVRS) “reduction pneumoplasty” was first described in 1957 by Otto Brantigan [3] and was later reintroduced and refined by Joel Cooper [4]. The goals of lung volume reduction are to remove emphysematous lung to improve hyperinflation, diaphragmatic mobility and expiratory flow. The seminal trial was National Emphysema Treatment Trial (NETT) and results were published in 2003 which showed that a subset of patients who had upper lobe predominant emphysema and low baseline exercise capacity did benefit from LVRS and others did not [4].

Endobronchial Lung Volume Reduction (ELVR) strategies include devices that completely occlude an airway causing lobar collapse, that mechanically decrease the lung volume and mechanisms that induce inflammation and cause subsequent fibrosis thereby decreasing lung volume. Initially, complete bilateral upper lobe treatment was attempted, but this led to pneumothorax. Additionally, some patients were noted to have benefit without lobar collapse. This effect was postulated to be secondary to improvements in dynamic hyperinflation, collateral ventilation, ventilation/perfusion matching and redirection of ventilation to more functional alveolar units. The variables used to predict which form of bronchoscopic treatment would be most beneficial include collateral ventilation and disease heterogeneity [6]. Approaches have included the placement of endobronchial valves and, endobronchial coils, as well as biological agents to induce scarring and airway bypass approaches, either endobronchially or transpleurally.

Bronchial Valves

The working principle of endo/intra bronchial valves (EBVs or IBVs) is to allow air and secretions to come out while restricting air-entry, thus excluding the nonfunctional emphysematous region from ventilation and reducing dynamic air-trapping [7]. This procedure is suitable in heterogeneous, upper-lobe predominant emphysema without collateral ventilation. A limitation to this approach is the presence of interlobar collateral ventilation. Where this occurs, occlusion of all segmental bronchi will not isolate a lobe, because air can still enter through pathological channels from adjacent damaged lung. There are two types of valve.

Spiration intrabronchial valve

Umbrella-shaped device with a nitinol frame consisting 5 distal anchors and 5 proximal struts with a central rod covered in a thin layer of polyurethane (Figure 1).
Figure 1: Endobronchial valve 6mm in diameter (spiration).

Zephyr valve

Figure 2: Endobronchial valve (zephyr) valve.

Duck-bill shaped, silicone-covered one way valve within a self-expanding stent that contains a flexible retainer which expands to anchor it to the airway and ensure an airtight seal (Figure 2). It is possible that up to 6 or more valves may be required for the complete blockade of a lobe. The procedure is usually performed under general anesthesia with patient intubated, on spontaneous assisted ventilation. EBVs by occluding airways increased the airway resistance thus diverting air to less emphysematous part of lung and decreasing air-trapping and dynamic hyperinflation is causes the inter lobar shift of ventilation from treated to untreated portion of lung thereby decreasing dead space and increasing ventilation thus reducing previously hypoxia induced vasoconstriction in the healthy areas of lung [8]. Is not only improves ventilation-perfusion mismatch but also has beneficial effect on pulmonary hypertension [8] (Table 1). Surgical lung volume reduction is currently more effective than bronchoscopic lung volume reduction both in regard to changes in lung volumes and exercise capacity. However, morbidity and mortality are much lower in bronchoscopic lung volume reduction than with the surgical procedure. We have recently shown that implantation of a new generation of intra bronchial valves an umbrella-shaped, self- expanding device can be performed safely via flexible bronchoscopy under conscious sedation with propofol, even in patients with major contraindications for surgical volume reduction.

Table 1:

<table>
<thead>
<tr>
<th>Contraindications for Surgical Lung Volume Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Persistent smoking</td>
</tr>
<tr>
<td>Not fit for pulmonary rehabilitation</td>
</tr>
<tr>
<td>Pulmonary arterial hypertension (mPAP&gt;35 mm Hg)</td>
</tr>
<tr>
<td>Very severe obstruction (FEV1 &lt;20% predicted)</td>
</tr>
<tr>
<td>Severe impairment of gas exchange</td>
</tr>
<tr>
<td>Diffusion capacity &lt;20% predicted</td>
</tr>
<tr>
<td>Severe hypoxemia</td>
</tr>
<tr>
<td>Hypercapnia</td>
</tr>
<tr>
<td>Major comorbidities</td>
</tr>
<tr>
<td>Lung infection / bronchiectasis</td>
</tr>
</tbody>
</table>

Biologic Lung Volume Reduction

Fibrinogen suspension and thrombin solution, which polymerize to a hydrogel as they come in contact with one another induces a localized inflammatory reaction that causes atelectasis by occlusion and remodeling over 4- to 6-weeks.

A. Improves FEV1, FVC, RV/TLC, RV, dyspnea scores and SGRQ
B. Can be used in homogeneous disease, is not affected by collateral ventilation
C. Irreversible

Aeriseal

A. A synthetic version of biologic lung volume reduction system
B. No human blood products are used which decreases risk of transmissible diseases
C. Initially uses a primer to remove surfactant which causes atelectasis and then the synthetic hydrogel is introduced which causes inflammation resulting in scarring and remodeling over several weeks
D. Improves FEV1, RV and SGRQ
E. Has been studied in upper lobe predominant disease
F. Is not affected by collateral ventilation
G. Irreversible

Bronchoscopic Thermal Vapor Ablation

A. Use of heated water to produce thermal injury creating a localized inflammatory response followed by permanent fibrosis and atelectasis.
B. Studied in heterogeneous, upper-lobe predominant disease
C. Improves FEV1, RV, 6-minute walk distance, BODE index, SGRQ
D. Not affected by collateral ventilation
E. Irreversible

Coils
A. Catheter loaded straightened nitinol coil over a guide wire. On coil deployment the straightened coil then conforms to its predetermined shape
B. Coil deployment bends the airway resulting in compression of adjacent lung tissue
C. Creates local lung volume reduction and restores elastic recoil of the healthier lung compartments.
D. Improves SGRQ, FEV1, RV and 6 minute walk distance
E. Not affected by collateral ventilation
F. Unclear if it can be reversed

Airway bypass
A. Initially created to treat homogeneous disease
B. Placement of drug-eluting stent-supported fenestrations in the airway wall to allow for decrease in air trapping and an increased volume of air expelled during forced exhalations
C. Was not successful: improvements were transient, the procedure is technically difficult and the stents are easily displaced or obstructed

A recently published randomized, controlled study, STELVIO, found that in patients with severe emphysema who were preselected on the basis of a proven absence of interlobar collateral ventilation, endobronchial-valve treatment improved pulmonary function, exercise capacity, and quality of life, even when we considered patients in whom valve removal was required. Adverse events, including potentially life-threatening events, occurred and required careful follow-up.

Conclusion
ELVR appears to be safe and will hopefully become an attractive minimally-invasive alternative for patients with severe COPD. Although, ELVR remains experimental, emerging data is promising. Refining patient selection and measurements to best qualify and quantify improvement outcomes is the current challenge.

References

Your next submission with Juniper Publishers will reach you the below assets
- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php

How to cite this article: Surya k, Jyoti B. Bronchoscopic Lung Volume Reduction for Emphysema. Int J cell Sci & mol biol. 2017; 2(3) : 555588. DOI : 10.19080/IJCSMB.2017.02.555588